• In recent days, Viridian Therapeutics has come under renewed attention after Amgen reported positive Phase 3 results for a subcutaneous version of Tepezza in moderate to severe active thyroid eye disease, raising questions about future treatment options in this space.
• This competing clinical success places a spotlight on how Viridian’s own thyroid eye disease pipeline could fit into an evolving treatment landscape and patient preference profile.
• Next, we’ll examine how Amgen’s subcutaneous Tepezza data may influence Viridian’s investment narrative and expectations for its thyroid eye disease program.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Viridian Therapeutics' Investment Narrative?

To own Viridian today, you really have to believe its thyroid eye disease franchise can still carve out meaningful space beside Tepezza, even after Amgen’s positive subcutaneous Phase 3 data hit the stock hard and prompted cuts to at least one price target. The near term story still revolves around veligrotug’s Priority Review, the planned US and European filings, and how convincingly the REVEAL-2 data can reinforce the “best-in-class” thesis across proptosis, diplopia and safety. What has changed is the competitive bar: a convenient subcutaneous Tepezza could compress Viridian’s pricing power, share potential or timelines if payers and physicians are satisfied with an incumbent option. At the same time, Viridian remains unprofitable with a history of shareholder dilution, so execution on launch and trial milestones now matters even more.

However, there is one specific risk around future funding that investors should understand in detail. Despite retreating, Viridian Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span from just US$0.18 to over US$170 per share, underlining how far apart individual views can be. Set against that backdrop, the recent competitive TED data and Viridian’s continued losses give you strong reasons to compare several of these perspectives before deciding how its story might play out.

Explore 3 other fair value estimates on Viridian Therapeutics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viridian Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Viridian Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viridian Therapeutics' overall financial health at a glance.

No Opportunity In Viridian Therapeutics?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.